Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Operating Officer | July 21, 2020 | July 23, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date July 21, 2020 · Filed July 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 220,867 |
Ending reported balance
After 2020-07-22 transaction · row 15
15 source rows · reconciled sequenceRow 1 · 2020-07-21 · Exercise / conversion · Acquired 300 · Balance 221,167 Row 2 · 2020-07-21 · Sale · Disposed 300 · Balance 220,867 F1: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 300 shares in multiple trades at prices ranging from $65.00 to $65.11. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2020-07-21 · Exercise / conversion · Acquired 3,021 · Balance 223,888 Row 4 · 2020-07-21 · Sale · Disposed 3,021 · Balance 220,867 F2: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 3,021 shares in multiple trades at prices ranging from $65.00 to $65.31. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2020-07-22 · Exercise / conversion · Acquired 8,426 · Balance 229,293 Row 6 · 2020-07-22 · Sale · Disposed 400 · Balance 228,893 F3: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 400 shares in multiple trades at prices ranging from $65.16 to $65.82. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2020-07-22 · Sale · Disposed 4,228 · Balance 224,665 F4: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 4,228 shares in multiple trades at prices ranging from $66.21 to $67.19. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 8 · 2020-07-22 · Sale · Disposed 3,798 · Balance 220,867 F5: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 3,798 shares in multiple trades at prices ranging from $67.21 to $67.80. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 9 · 2020-07-22 · Exercise / conversion · Acquired 3,774 · Balance 224,641 Row 10 · 2020-07-22 · Sale · Disposed 1,151 · Balance 223,490 F6: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 1,151 shares in multiple trades at prices ranging from $65.76 to $66.75. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 11 · 2020-07-22 · Sale · Disposed 2,623 · Balance 220,867 F7: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 2,623 shares in multiple trades at prices ranging from $66.79 to $67.64. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 12 · 2020-07-22 · Exercise / conversion · Acquired 30,772 · Balance 251,639 Row 13 · 2020-07-22 · Sale · Disposed 1,380 · Balance 250,259 F8: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 1,380 shares in multiple trades at prices ranging from $65.00 to $65.92. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 14 · 2020-07-22 · Sale · Disposed 12,217 · Balance 238,042 F9: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 12,217 shares in multiple trades at prices ranging from $66.03 to $67.02. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Row 15 · 2020-07-22 · Sale · Disposed 17,175 · Balance 220,867 F10: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 17,175 shares in multiple trades at prices ranging from $67.04 to $67.94. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. |
| Options to Buy Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $11.46 · Expires 2026-02-24 | Direct | 8,426 |
Reported balance
After 2020-07-21 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2020-07-21 · Exercise / conversion · Disposed 300 · Balance 8,426 F11: Fully vested as of the date hereof. |
| Options to Buy Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $21.15 · Expires 2028-02-26 | Direct | 98,358 |
Reported balance
After 2020-07-21 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2020-07-21 · Exercise / conversion · Disposed 3,021 · Balance 98,358 F12: Fully-vested as of the date hereof except for options to purchase 67,586 ordinary shares, which will vest in equal installments on each of 2/26/21 and 2/26/22, subject to the reporting person's continued employment through such dates. |
| Options to Buy Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $11.46 · Expires 2026-02-24 | Direct | 0 |
Reported balance
After 2020-07-22 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2020-07-22 · Exercise / conversion · Disposed 8,426 · Balance 0 F11: Fully vested as of the date hereof. |
| Options to Buy Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $11.46 · Expires 2026-02-24 | Direct | 0 |
Reported balance
After 2020-07-22 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2020-07-22 · Exercise / conversion · Disposed 3,774 · Balance 0 F11: Fully vested as of the date hereof. |
| Options to Buy Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $21.15 · Expires 2028-02-26 | Direct | 67,586 |
Reported balance
After 2020-07-22 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2020-07-22 · Exercise / conversion · Disposed 30,772 · Balance 67,586 F13: Options to purchase 67,586 ordinary shares will vest and become exercisable in equal installments on each of 2/26/21 and 2/26/22, subject to the reporting person's continued employment through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 300 shares in multiple trades at prices ranging from $65.00 to $65.11. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F2: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 3,021 shares in multiple trades at prices ranging from $65.00 to $65.31. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F3: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 400 shares in multiple trades at prices ranging from $65.16 to $65.82. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F4: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 4,228 shares in multiple trades at prices ranging from $66.21 to $67.19. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F5: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 3,798 shares in multiple trades at prices ranging from $67.21 to $67.80. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F6: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 1,151 shares in multiple trades at prices ranging from $65.76 to $66.75. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F7: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 2,623 shares in multiple trades at prices ranging from $66.79 to $67.64. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F8: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 1,380 shares in multiple trades at prices ranging from $65.00 to $65.92. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F9: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 12,217 shares in multiple trades at prices ranging from $66.03 to $67.02. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F10: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 17,175 shares in multiple trades at prices ranging from $67.04 to $67.94. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
F11: Fully vested as of the date hereof.
F12: Fully-vested as of the date hereof except for options to purchase 67,586 ordinary shares, which will vest in equal installments on each of 2/26/21 and 2/26/22, subject to the reporting person's continued employment through such dates.
F13: Options to purchase 67,586 ordinary shares will vest and become exercisable in equal installments on each of 2/26/21 and 2/26/22, subject to the reporting person's continued employment through such dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 22, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 30,772 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · derivative · entry 20 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,586 Underlying: Ordinary Shares · 30,772 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: Options to purchase 67,586 ordinary shares will vest and become exercisable in equal installments on each of 2/26/21 and 2/26/22, subject to the reporting person's continued employment through such dates. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 3,774 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · derivative · entry 19 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,774 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 8,426 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · derivative · entry 18 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,426 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 17,175 | $67.39 | $1,157,474.78 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · nonDerivative · entry 15 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,867 F10 · price: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 17,175 shares in multiple trades at prices ranging from $67.04 to $67.94. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 12,217 | $66.66 | $814,336.35 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · nonDerivative · entry 14 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,042 F9 · price: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 12,217 shares in multiple trades at prices ranging from $66.03 to $67.02. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,380 | $65.49 | $90,374.82 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · nonDerivative · entry 13 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,259 F8 · price: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 1,380 shares in multiple trades at prices ranging from $65.00 to $65.92. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 30,772 | $21.15 | $650,827.80 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · nonDerivative · entry 12 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,623 | $67.28 | $176,470.19 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · nonDerivative · entry 11 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,867 F7 · price: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 2,623 shares in multiple trades at prices ranging from $66.79 to $67.64. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,151 | $66.50 | $76,539.20 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · nonDerivative · entry 10 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,490 F6 · price: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 1,151 shares in multiple trades at prices ranging from $65.76 to $66.75. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 3,774 | $11.46 | $43,250.04 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · nonDerivative · entry 9 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,798 | $67.48 | $256,273.85 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · nonDerivative · entry 8 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,867 F5 · price: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 3,798 shares in multiple trades at prices ranging from $67.21 to $67.80. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,228 | $66.77 | $282,286.65 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · nonDerivative · entry 7 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,665 F4 · price: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 4,228 shares in multiple trades at prices ranging from $66.21 to $67.19. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 400 | $65.53 | $26,210.00 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · nonDerivative · entry 6 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,893 F3 · price: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 400 shares in multiple trades at prices ranging from $65.16 to $65.82. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 8,426 | $11.46 | $96,561.96 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · nonDerivative · entry 5 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 3,021 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · derivative · entry 17 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,358 Underlying: Ordinary Shares · 3,021 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Fully-vested as of the date hereof except for options to purchase 67,586 ordinary shares, which will vest in equal installments on each of 2/26/21 and 2/26/22, subject to the reporting person's continued employment through such dates. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 300 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · derivative · entry 16 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,426 Underlying: Ordinary Shares · 300 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,021 | $65.06 | $196,552.30 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · nonDerivative · entry 4 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,867 F2 · price: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 3,021 shares in multiple trades at prices ranging from $65.00 to $65.31. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 3,021 | $21.15 | $63,894.15 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · nonDerivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 300 | $65.07 | $19,520.10 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,867 F1 · price: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 300 shares in multiple trades at prices ranging from $65.00 to $65.11. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 19:43 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 300 | $11.46 | $3,438.00 |
DisclosureSEC source: 0001645113-20-000101 · wf-form4_159554780981314.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 17:03 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 35,745 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001645113-20-000051 · wf-form4_158698459073166.xml · derivative · entry 8 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,514 Underlying: Ordinary Shares · 35,745 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 17:03 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 377 | $71.75 | $27,050.88 |
DisclosureSEC source: 0001645113-20-000051 · wf-form4_158698459073166.xml · nonDerivative · entry 6 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,867 F4 · price: On April 14, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 377 shares in multiple trades at prices ranging from $71.64 to $71.88. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 17:03 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 27,142 | $70.99 | $1,926,919.15 |
DisclosureSEC source: 0001645113-20-000051 · wf-form4_158698459073166.xml · nonDerivative · entry 5 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,244 F3 · price: On April 14, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 27,142 shares in multiple trades at prices ranging from $70.62 to $71.51. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 17:03 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 35,745 | $7.15 | $255,576.75 |
DisclosureSEC source: 0001645113-20-000051 · wf-form4_158698459073166.xml · nonDerivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:03 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 22,755 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001645113-20-000051 · wf-form4_158698459073166.xml · derivative · entry 7 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,259 Underlying: Ordinary Shares · 22,755 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:03 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 8,226 | $70.18 | $577,317.13 |
DisclosureSEC source: 0001645113-20-000051 · wf-form4_158698459073166.xml · nonDerivative · entry 4 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,386 F2 · price: On April 14, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 8,226 shares in multiple trades at prices ranging from $69.62 to $70.61. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:03 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 22,755 | $69.01 | $1,570,277.04 |
DisclosureSEC source: 0001645113-20-000051 · wf-form4_158698459073166.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,867 F1 · price: On April 13, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 22,755 shares in multiple trades at prices ranging from $69.00 to $69.42. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:03 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 22,755 | $7.15 | $162,698.25 |
DisclosureSEC source: 0001645113-20-000051 · wf-form4_158698459073166.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 16:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 2,274 | $69.53 | $158,120.32 |
DisclosureSEC source: 0001645113-20-000050 · wf-form4_158387171792410.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,867 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units vested on March 5, 2020. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 18:55 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 27,794 | $0.00 Strike: $69.37 | $0.00 |
DisclosureSEC source: 0001645113-20-000039 · wf-form4_158345248438324.xml · derivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,794 Underlying: Ordinary Shares · 27,794 shares Expires 2030-03-02 F2 · derivative.exercise_date: Options to buy 27,794 ordinary shares will vest and become exercisable in equal installments on each of March 3, 2021, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 18:55 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 14,415 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000039 · wf-form4_158345248438324.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,141 F1 · shares: Represents restricted share units that are scheduled to vest on March 3, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 17:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,673 | $72.22 | $193,030.70 |
DisclosureSEC source: 0001645113-20-000033 · wf-form4_158318741628984.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,726 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 17:17 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 6,173 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000033 · wf-form4_158318741628984.xml · derivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,172 Underlying: Ordinary Shares · 6,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 17:17 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 6,173 | $79.45 | $490,444.85 |
DisclosureSEC source: 0001645113-20-000033 · wf-form4_158318741628984.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 17:10 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 11,647 | $81.16 | $945,223.93 |
DisclosureSEC source: 0001645113-20-000012 · wf-form4_158275502371144.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,226 Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 17:10 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 31,199 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000012 · wf-form4_158275502371144.xml · derivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 31,199 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 17:10 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 31,199 | $88.26 | $2,753,623.74 |
DisclosureSEC source: 0001645113-20-000012 · wf-form4_158275502371144.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 16:27 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 33,793 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001628280-19-013505 · wf-form4_157307564482872.xml · derivative · entry 9 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,651 Underlying: Ordinary Shares · 33,793 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 16:27 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 36,957 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001628280-19-013505 · wf-form4_157307564482872.xml · derivative · entry 8 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 36,957 shares Expires 2025-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 16:27 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 10,069 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001628280-19-013505 · wf-form4_157307564482872.xml · derivative · entry 7 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,069 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 16:27 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 33,793 | $79.00 | $2,669,647.00 |
DisclosureSEC source: 0001628280-19-013505 · wf-form4_157307564482872.xml · nonDerivative · entry 6 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,674 F1 · security: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 16:27 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 33,793 | $21.15 | $714,721.95 |
DisclosureSEC source: 0001628280-19-013505 · wf-form4_157307564482872.xml · nonDerivative · entry 5 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 16:27 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 36,957 | $79.00 | $2,919,603.00 |
DisclosureSEC source: 0001628280-19-013505 · wf-form4_157307564482872.xml · nonDerivative · entry 4 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,674 F1 · security: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 16:27 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 36,957 | $22.00 | $813,054.00 |
DisclosureSEC source: 0001628280-19-013505 · wf-form4_157307564482872.xml · nonDerivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 16:27 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 10,069 | $79.00 | $795,451.00 |
DisclosureSEC source: 0001628280-19-013505 · wf-form4_157307564482872.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,674 F1 · security: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 16:27 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 10,069 | $14.37 | $144,691.53 |
DisclosureSEC source: 0001628280-19-013505 · wf-form4_157307564482872.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 16:01 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 110,868 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001209191-19-038446 · doc4.xml · derivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,957 Underlying: Ordinary Shares · 110,868 shares Expires 2025-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 16:01 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 110,868 | $60.00 | $6,652,080.00 |
DisclosureSEC source: 0001209191-19-038446 · doc4.xml · nonDerivative · entry 2 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,674 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 16:01 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 110,868 | $22.00 | $2,439,096.00 |
DisclosureSEC source: 0001209191-19-038446 · doc4.xml · nonDerivative · entry 1 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 16:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 5,999 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001209191-19-035774 · doc4.xml · derivative · entry 3 Ambrogi Michael J. · CIK 0001654363 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,014 Underlying: Ordinary Shares · 5,999 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.